Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel with or without rhenium-188 HEDP for metastatic castration-resistant prostate cancer after docetaxel
NL-OMON22536Phase 2Not yet recruiting
- Sponsor
- Meander Medical Center
- Start
- Feb 2012
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cabazitaxel and Rhenium-188-HEDP in prostate cancer (PCa), sponsored by Meander Medical Center. Planned start Feb 2012; status: not yet recruiting.
02
Drugs
cabazitaxelRhenium-188-HEDP
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON22536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22536.